Capricor Therapeutics Debt to Equity Ratio 2010-2024 | CAPR
Current and historical debt to equity ratio values for Capricor Therapeutics (CAPR) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Capricor Therapeutics debt/equity for the three months ending September 30, 2024 was 0.00.
| Capricor Therapeutics Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2024-09-30 | $0.03B | $0.07B | 0.36 |
| 2024-06-30 | $0.03B | $0.01B | 2.33 |
| 2024-03-31 | $0.03B | $0.02B | 1.68 |
| 2023-12-31 | $0.04B | $0.02B | 1.60 |
| 2023-09-30 | $0.04B | $-0.00B | -21.78 |
| 2023-06-30 | $0.04B | $0.00B | 15.85 |
| 2023-03-31 | $0.05B | $0.01B | 7.68 |
| 2022-12-31 | $0.04B | $0.01B | 3.25 |
| 2022-09-30 | $0.04B | $0.02B | 2.50 |
| 2022-06-30 | $0.04B | $0.02B | 2.10 |
| 2022-03-31 | $0.04B | $0.03B | 1.64 |
| 2021-12-31 | $0.01B | $0.03B | 0.32 |
| 2021-09-30 | $0.01B | $0.04B | 0.17 |
| 2021-06-30 | $0.01B | $0.03B | 0.20 |
| 2021-03-31 | $0.01B | $0.04B | 0.20 |
| 2020-12-31 | $0.01B | $0.03B | 0.23 |
| 2020-09-30 | $0.01B | $0.03B | 0.19 |
| 2020-06-30 | $0.01B | $0.03B | 0.17 |
| 2020-03-31 | $0.01B | $0.01B | 0.49 |
| 2019-12-31 | $0.00B | $0.01B | 0.63 |
| 2019-09-30 | $0.00B | $0.00B | 1.22 |
| 2019-06-30 | $0.01B | $0.00B | 2.09 |
| 2019-03-31 | $0.01B | $0.00B | 1.30 |
| 2018-12-31 | $0.01B | $0.01B | 1.00 |
| 2018-09-30 | $0.01B | $0.01B | 0.75 |
| 2018-06-30 | $0.01B | $0.01B | 0.49 |
| 2018-03-31 | $0.01B | $0.01B | 0.46 |
| 2017-12-31 | $0.01B | $0.01B | 0.45 |
| 2017-09-30 | $0.02B | $-0.00B | -4.70 |
| 2017-06-30 | $0.02B | $-0.01B | -3.16 |
| 2017-03-31 | $0.02B | $-0.01B | -2.96 |
| 2016-12-31 | $0.02B | $-0.00B | -5.68 |
| 2016-09-30 | $0.02B | $0.00B | 497.41 |
| 2016-06-30 | $0.02B | $-0.01B | -3.72 |
| 2016-03-31 | $0.02B | $-0.00B | -16.69 |
| 2015-12-31 | $0.02B | $-0.00B | -16.57 |
| 2015-09-30 | $0.02B | $0.00B | 9.33 |
| 2015-06-30 | $0.02B | $0.01B | 4.20 |
| 2015-03-31 | $0.02B | $0.01B | 2.75 |
| 2014-12-31 | $0.02B | $-0.01B | -3.18 |
| 2014-09-30 | $0.02B | $-0.00B | -4.64 |
| 2014-06-30 | $0.02B | $-0.00B | -6.98 |
| 2014-03-31 | $0.02B | $-0.00B | -10.63 |
| 2013-12-31 | $0.01B | $-0.00B | -11.35 |
| 2013-09-30 | $0.00B | $-0.00B | -1.07 |
| 2013-06-30 | $0.00B | $-0.00B | -1.24 |
| 2013-03-31 | $0.00B | $-0.00B | -1.65 |
| 2012-12-31 | $0.00B | $0.01B | 0.11 |
| 2012-09-30 | $0.00B | $0.00B | 17.21 |
| 2012-06-30 | $0.00B | $0.00B | 0.84 |
| 2012-03-31 | $0.00B | $0.00B | 2.10 |
| 2011-12-31 | $0.00B | $0.00B | 0.65 |
| 2011-09-30 | $0.00B | $0.00B | 0.30 |
| 2011-06-30 | $0.00B | $0.00B | 0.13 |
| 2011-03-31 | $0.00B | $0.00B | 0.44 |
| 2010-12-31 | $0.00B | $0.00B | 0.41 |
| 2010-09-30 | $0.00B | $0.00B | 0.46 |
| 2010-06-30 | $0.00B | $0.01B | 0.24 |
| 2010-03-31 | $0.00B | $0.00B | 0.60 |
| 2009-12-31 | $0.00B | $0.00B | 0.21 |
| 2009-09-30 | $0.00B | $0.00B | 0.21 |
| 2009-06-30 | $0.00B | $0.00B | 0.24 |
| 2009-03-31 | $0.00B | $0.00B | 0.22 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.847B | $0.025B |
| Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $204.249B | 26.05 |
| Stryker (SYK) | United States | $146.711B | 33.06 |
| Boston Scientific (BSX) | United States | $132.644B | 38.14 |
| EssilorLuxottica (ESLOY) | France | $112.106B | 0.00 |
| Medtronic (MDT) | Ireland | $110.562B | 16.42 |
| Haleon (HLN) | United Kingdom | $43.682B | 28.38 |
| Lonza Group Ag (LZAGY) | Switzerland | $42.166B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $37.665B | 19.54 |
| ResMed (RMD) | United States | $35.786B | 29.41 |
| Terumo (TRUMY) | Japan | $29.739B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $24.805B | 18.99 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.942B | 13.97 |
| Insulet (PODD) | United States | $18.443B | 73.44 |
| Baxter (BAX) | United States | $16.957B | 11.03 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.065B | 0.00 |
| BellRing Brands (BRBR) | United States | $10.158B | 40.72 |
| Bio-Rad Laboratories (BIO) | United States | $9.320B | 31.68 |
| Demant (WILYY) | Denmark | $8.342B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.294B | 14.62 |
| TG Therapeutics (TGTX) | United States | $5.459B | 0.00 |
| Haemonetics (HAE) | United States | $4.297B | 20.97 |
| Prestige Consumer Healthcare (PBH) | United States | $4.192B | 20.85 |
| ICU Medical (ICUI) | United States | $4.125B | 39.27 |
| Perrigo (PRGO) | Ireland | $3.830B | 11.27 |
| Envista Holdings (NVST) | United States | $3.697B | 27.54 |
| Neogen (NEOG) | United States | $3.246B | 37.45 |
| Agios Pharmaceuticals (AGIO) | United States | $3.175B | 0.00 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.841B | 18.22 |
| QuidelOrtho (QDEL) | United States | $2.700B | 17.38 |
| LeMaitre Vascular (LMAT) | United States | $2.428B | 59.00 |
| Warby Parker (WRBY) | United States | $2.349B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.913B | 33.48 |
| AtriCure (ATRC) | United States | $1.742B | 0.00 |
| InMode (INMD) | Israel | $1.597B | 9.61 |
| AdaptHealth (AHCO) | United States | $1.326B | 9.48 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.318B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $1.267B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.207B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.962B | 16.96 |
| Owens & Minor (OMI) | United States | $0.952B | 7.44 |
| CeriBell (CBLL) | United States | $0.943B | 0.00 |
| National Vision Holdings (EYE) | United States | $0.918B | 30.68 |
| Evolus (EOLS) | United States | $0.798B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.684B | 30.25 |
| Omeros (OMER) | United States | $0.632B | 0.00 |
| Surmodics (SRDX) | United States | $0.563B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.533B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.522B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.468B | 0.00 |
| Quanterix (QTRX) | United States | $0.451B | 0.00 |
| ZimVie (ZIMV) | United States | $0.391B | 32.95 |
| Valneva SE (VALN) | France | $0.360B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.341B | 32.41 |
| Cerus (CERS) | United States | $0.332B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.330B | 0.00 |
| Biote (BTMD) | United States | $0.325B | 7.12 |
| OraSure Technologies (OSUR) | United States | $0.289B | 19.40 |
| Zynex (ZYXI) | United States | $0.263B | 55.07 |
| Aurora Cannabis (ACB) | Canada | $0.238B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.225B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.221B | 15.29 |
| High Tide (HITI) | Canada | $0.213B | 88.33 |
| MacroGenics (MGNX) | United States | $0.203B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.188B | 2.64 |
| Brainsway (BWAY) | Israel | $0.167B | 100.00 |
| Organigram Holdings (OGI) | Canada | $0.166B | 0.00 |
| Jin Medical (ZJYL) | China | $0.164B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.160B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.149B | 18.67 |
| TriSalus Life Sciences (TLSI) | United States | $0.138B | 0.00 |
| Fonar (FONR) | United States | $0.104B | 11.74 |
| Quipt Home Medical (QIPT) | United States | $0.104B | 0.00 |
| Veru (VERU) | United States | $0.099B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.094B | 23.40 |
| Ayr Wellness (AYRWF) | United States | $0.077B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.073B | 37.50 |
| Exagen (XGN) | United States | $0.072B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.065B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.063B | 0.00 |
| InterCure (INCR) | Israel | $0.062B | 0.00 |
| Modular Medical (MODD) | United States | $0.058B | 0.00 |
| MariMed (MRMD) | United States | $0.057B | 0.00 |
| Apyx Medical (APYX) | United States | $0.054B | 0.00 |
| Safety Shot (SHOT) | United States | $0.051B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.050B | 0.00 |
| ImmuCell (ICCC) | United States | $0.033B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.028B | 0.00 |
| Flora Growth (FLGC) | United States | $0.019B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.018B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.016B | 0.00 |
| Nephros (NEPH) | United States | $0.016B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.009B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Sharps Technology (STSS) | United States | $0.006B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Agape ATP (ATPC) | $0.006B | 0.00 | |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Senestech (SNES) | United States | $0.002B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 12.83 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |